Mark A. Hillman - Hillman Value Fund Investment Strategy & Portfolio Analysis

How Hillman Value Fund allocates capital, manages risk, and constructs its portfolio — based on SEC 13F filings.

As of Mar 31, 2026, Mark A. Hillman's Hillman Value Fund portfolio reflects a quant / systematic investor approach across 56 reported 13F positions. Portfolio returns are distributed across holdings, with the top five positions representing approximately 19% of total exposure. Across 56 reported holdings, economic exposure is broadly distributed across healthcare, consumer defensive companies, and technology without dominant single-name concentration. Exposure to high-growth and technology-oriented segments is moderate relative to peers, with performance weighted across healthcare, consumer staples, and basic materials. The portfolio exhibits low turnover, consistent with a buy-and-hold posture held through multiple reporting cycles. Distinctive traits include Long-Term Holder, Broadly Diversified, Economically Diversified.

Investment Style

Value, growth, quality, and behavioral classification from latest 13F holdings.

Quant / Systematic Investor

Primary type: Quant / Systematic Investor

Traits: Long-Term Holder, Broadly Diversified, Economically Diversified, Structurally Diversified

Turnover profile

Moderate

Holding horizon

Long-Term

Portfolio Construction

Concentration and position sizing in the latest filing.

Portfolio construction is lowly concentrated: top three names represent 11.3% of assets, top five 18.7%, and the largest single position is 3.8%.

Top 3 weight

11.3%

Top 5 weight

18.7%

Top 10 weight

35.6%

Largest position

3.8%

Top holdings: Biogen Inc., DuPont de Nemours, Inc., Warner Bros. Discovery, Inc. -, GSK plc, International Flavors & Fragran — view full holdings

Sector Preferences

Where capital is allocated by sector.

Capital is tilted toward Healthcare and Consumer Defensive, with 10 sectors represented in the latest filing.

Leading sectors: Healthcare, Consumer Defensive, Technology

View full sector allocation

Risk Framework

Concentration, diversification, and turnover tolerance.

This investor accepts low single-name risk (largest position 3.8%, top ten 35.6%) and high economic diversification (HHI 0.01). Turnover tolerance maps to a moderate profile.

Largest position

3.8%

Top 10 weight

35.6%

Max sector

27.9%

Diversification

High

Strategy Evolution

How the strategy changed between the two most recent filing periods.

Dec 31, 2025 → Mar 31, 2026

  • Largest holding changed from Warner Bros. Discovery, Inc. - to Biogen Inc..
  • Quarter-over-quarter portfolio weight turnover: 13.8%.

For trade-level changes, see the Activity page. View activity.

Similar Investors

Peer group with comparable portfolio behavior.

Similar-investor comparisons are coming soon.